Mouse monoclonal antibodies to several cell surface antigens of human ovarian and endometrial carcinomas have been produced. The distribution of the antigens was determined by mixed hemagglutination assays on 153 normal and malignant cell cultures of various types and by immunoperoxidase staining of frozen sections of 27 normal adult and 24 fetal tissues. Five distinct antigens were characterized. MD144 antigen was detected on only a single ovarian carcinoma cell line and has the biochemical properties of a lipid. MH55 antigen is weakly expressed on ovarian and uterine cancer cell lines but not on other cells and tissues tested. MF61 antigen was detected on an ovarian carcinoma and some renal carcinoma cell lines but not on other cell lines tested. It was also detected by immunoperoxidase staining in the noncellular follicles of the thyroid and in uterine glandular epithelial cells. This antigen also has the properties of a lipid. MF116 antigen was detected on a proportion of ovarian, uterine, renal, and bladder carcinoma and neuroblastoma cell lines and on normal kidney epithelial cell cultures but not on other cell lines tested. It was not detected in sections of any normal tissue tested using the immunoperoxidase method. MF116 was readily detected in the spent culture medium but not in detergent-solubilized extracts of metabolically radiolabeled cells. This shed antigen is a glycoprotein of Mr 105,000 and isoelectric point lower than pH 4.0. MH94 antigen was detected on a proportion of ovarian, uterine, colon, breast, lung, cervical, and pancreatic carcinoma cell lines. In tissue sections it was detected in many but not all epithelia, predominantly in secretory epithelial cells. Antibody MH94 did not immunoprecipitate a detectable antigen.
ABSTRACT
Mouse monoclonal antibodies to several cell surface antigens of human ovarian and endometrial carcinomas have been produced. The distribution of the antigens was determined by mixed hemagglutination assays on 153 normal and malignant cell cultures of various types and by immunoperoxidase staining of frozen sections of 27 normal adult and 24 fetal tissues. Five distinct antigens were characterized. MD144 antigen was detected on only a single ovarian carcinoma cell line and has the biochemical properties of a lipid. MH55 antigen is weakly expressed on ovarian and uterine cancer cell lines but not on other cells and tissues tested. MF61 antigen was detected on an ovarian carcinoma and some renal carcinoma cell lines but not on other cell lines tested. It was also detected by immunoperoxidase staining in the noncellular follicles of the thyroid and in uterine glandular epithelial cells. This antigen also has the properties of a lipid. MF116 antigen was detected on a proportion of ovarian, uterine, renal, and bladder carcinoma and neuroblastoma cell lines and on normal kidney epithelial cell cultures but not on other cell lines tested. It was not detected in sections of any normal tissue tested using the immunoperoxidase method. MF116 was readily detected in the spent culture medium but not in detergent-solubilized extracts of metabolically radiolabeled cells. This shed antigen is a glycoprotein of Mr 105,000 and isoelectric point lower than pH 4.0. MH94 antigen was detected on a proportion of ovarian, uterine, colon, breast, lung, cervical, and pancreatic carcinoma cell lines. In tissue sections it was detected in many but not all epithelia, predominantly in secretory epithelial cells. Antibody MH94 did not immunoprecipitate a detectable antigen.
Mouse monoclonal antibodies to human tumor cell surface antigens have been produced in many laboratories (reviewed in ref. 1) . The intention of these studies has frequently been to identify tumor-associated antigens that could be useful in tumor therapy or diagnosis. In practice, it was found that most or all of these antibodies recognized differentiation antigens. A few studies have described antibodies that detect very restricted antigens. Among these restricted antigens are the GD3 ganglioside antigen in melanoma/melanocytes (2, 3) and a novel ganglioside antigen that may provide a serum marker in colon, gastric, and pancreatic cancer patients (4). In the case of ovarian cancer, a mouse monoclonal antibody reactive with cryostat sections of S50% of ovarian carcinomas but not with normal tissues, except fallopian tube, endometrium, and endocervix, has been described (5, 6) .
In this report, we describe studies on the production of mouse monoclonal antibodies to ovarian and endometrial cancer. The identification of five distinct cell surface antigens is described.
MATERIALS AND METHODS
Target Cells. Cell lines used are listed in Table 1 and were cultured as described (7) (8) (9) . Cultures of normal human fibroblasts, kidney epithelial cells, and melanocytes have also been described (7) (8) (9) . Normal blood mononuclear cells were obtained by centrifuging heparinized blood onto a layer of Ficoll-Paque (Pharmacia). Total blood leukocytes were obtained by collecting the buffy coat after centrifugation for 10 min at 600 x g in 100-,l capillary tubes.
Production of Mouse Monoclonal Antibodies. BALB/c or (BALB/c x C57BL/6)F1 mice were immunized with either the ovarian carcinoma SK-OV-3 or 2774 or the endometrial carcinoma SK-UT-1 cell lines. Intraperitoneal injections of =100 ,ul of packed cells were given two to five times at intervals of 2 weeks. Three days after the last injection, the fusion of immune spleen cells with mouse myeloma MOPC-21 NS/1 cells was performed as described (10) . Culture supernatants were monitored for antibody activity by the antimouse Ig mixed hemagglutination assay (MHA) on a panel of cultured cells consisting of the immunizing cell line and other types of human tumor cells. Cloned hybridoma cells were injected subcutaneously into nu/nu mice. Sera from mice with progressive growing tumors were collected and used for serological and biochemical characterization. Antibody subclass was determined by double diffusion in agar with anti-Ig heavy chain-specific reagents (Bionetics, Kensington, MD). Serological Procedures. The MHA, on adherent and nonadherent (11) target cells using rabbit anti-mouse Ig and goat anti-mouse IgM, has been described (8, 12) . Monoclonal sera were titrated starting at 10-3. To confirm the specificity of antibodies, absorption tests were performed with the immunizing cell line and three melanomas (SK-MEL-28, SK-MEL-37, and MeWo), three astrocytomas (SK-MG-1, SK-MG-3, and U373 MG), three carcinomas (SK-BR-3, SK-LC-6, and Scaber), one T-cell leukemia (MOLT-4), one B-cell leukemia (Raji), and human erythrocytes. Absorption procedures have been described (7) .
To The titer of the antibody was defined as the highest dilution producing at least 50% rosetting in the MHA assay. 0, 1 x 10-1_1 X 10-6; Q, positive reaction but with <50% rosetting at 10-' dilution of antibody; 0, no reactivity at antibody dilution of 10-3. monoclonal antibody (nu/nu mouse serum at 1:500), biotinylated horse anti-mouse Ig, and complexes of avidin and biotinylated horseradish peroxidase (Vectastain reagents, Vector Laboratories, Burlingame, CA), following procedures recommended by the manufacturer. For particular tissues that had excessive background with this procedure-namely, the kidney, liver, and pancreas-a double sandwich was used, which comprised monoclonal sera at 1:200 and peroxidase-conjugated anti-mouse Ig (DAKO P161) at 1:50. To ensure that fixation did not destroy the antigen investigated, each antibody was first tested on sections of tissue culture cells frozen in 10% dimethyl sulfoxide at 50% packed cell volume/volume. All antibodies tested were positive in this assay, when the immunizing cell line was used as the target.
Immunofluorescent staining of blood leukocytes in suspension was performed as described (14) with fluoresceinconjugated goat anti-mouse Ig (Cappel Laboratories, Cochranville, PA) at 1:40 and monoclonal sera at 1:50. Lymphocytes and granulocytes were distinguished by morphology.
Immunoprecipitation Procedures. Each antibody was tested for its ability to precipitate an antigen from detergent-solubilized extracts of the immunizing cell after labeling by three methods: metabolic incorporation of [3H]glucosamine (15) , metabolic incorporation of [35S]methionine (10) , or Chloramine-T 125I labeling of solubilized cell membranes (16) . Nonidet P-40 solubilization of labeled cells and concanavalin A (Con A)-Sepharose fractionation of labeled extracts, used in some experiments, have been described (10, 15, 16) , as have immunoprecipitation procedures for 1251-labeled samples, using Staphylococcus aureus (16) . Aliquots of 2 x 106 35S cpm from unfractionated cell extracts were handled similarly, except that preclearing was omitted.
From the Con A eluate fraction of 35S-labeled extracts and for 3H-labeled extracts, aliquots of 2 x 105 cpm and different washing buffers (17) were used. Precipitated molecules were extracted with 60 ,ul of 0.01 M Tris-HCl, pH 7.2/2.0%were analyzed by polyacrylamide gel electrophoresis (10, 18) , using 9% gels and by two-dimensional electrophoresis (15, 19 In tissue sections, antibody MF61 reacted with two normal tissues: glandular epithelial cells of the adult and fetal uterus and the noncellular follicles of the thyroid (Fig. 2A) (Fig. 1) . If the antigen was not reduced, it migrated slightly faster, indicating some intrachain disulfide bonds (not shown). The iso- (22) and on human tumors (23) , present data indicate that these antigens are proteins or glycoproteins (24) (25) (26) and therefore differ in this respect from MD144. MF61 has an unusual distribution in normal tissue, being present in the noncellular follicles of the thyroid and in uterine glandular epithelial cells. The dominant antigen of the thyroid colloid is thyroglobulin, but antibody MF61 was not reactive with human thyroglobulin. A second colloid antigen has been described (27) A number of ovarian tumor antigens have been detected by using xenogeneic polyclonal sera (reviewed in ref. 28 ) but none of them seems to be related to the antigens described above. Other laboratories (5, 6, 29) have also described monoclonal antibodies to human ovarian carcinoma, but again, these appear to be different in specificity from those described in this study.
The five antibodies described were selected from a large number of hybridoma antibodies produced to ovarian and endometrial cancer cell lines. One problem in attempting to produce antibodies to restricted antigens of epithelial tumors is a tendency to produce many antibodies to common, strongly antigenic components. This factor might be overcome by removing strong antigens from a solubilized cell extract, by the use of immunoadsorbents, before immunization. Another factor is that only a small fraction of ovarian carcinomas can be grown and maintained in tissue culture. Therefore, immunizations with fresh tumor cells may be needed to detect the whole spectrum of ovarian and endometrial tumor antigens.
